

Receipt date: 03/17/2006

10554036 - GAU: 1626

PTO/SB/08A (07-05)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary.

Sheet 1 of 4

Complete if Known

Application Number	10/554,036
Filing Date	October 20, 2005
First Named Inventor	Besidski
Art Unit	UNKNOWN
Examiner Name	Unknown STOCKTON
Attorney Docket Number	101023-1P US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	FOREIGN PATENT DOCUMENT		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T#
		Foreign Patent Document	Publication Date MM-DD-YYYY			
		Country Code*Number *Kind Code* (if known)				
A4	EP 0599382		06-01-1994	Eastman Kodak Company		
A5	EP 0599384		06-01-1994	Eastman Kodak Company		
A6	WO 94/14801		07-07-1994	Smithkline Beecham PLC		
A7	WO 01/12188		02-22-2001	Pharmacia & Upjohn et al.		
A8	WO 02/090326		11-14-2002	Smithkline Beecham PLC		
A9	WO 02/42273		05-30-2002	Bristol-Myers Squibb Co.		

Examiner Signature	/Laura L. Stockton/	Date Considered	12/04/2008
-----------------------	---------------------	--------------------	------------

⁶EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §809. Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to applicant. ⁷Applicant's unique citation designation number (optional). ⁸See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁹Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹⁰For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹¹Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ¹²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

(you need assistance in completing the form, call 1-800-PTC-9199 (1-800-765-9199) and select option 2.)

Receipt date: 03/17/2006

10554036 - GAU: 1626

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	10/554,036
Filing Date	October 20, 2005
First Named Inventor	Besidski
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	101023-1P LIS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ * Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
	A10	WO 03/014064	02-20-2003	Bayer Aktiengesellschaft	T+
	A11	WO 03/037274	05-08-2003	Icagen, Inc.	
	A12	WO 2004/011440	02-05-2004	Banyu Pharmaceutical Co.	
	A13	WO 2004/056774	07-08-2004	Neurogen Corporation	
	A14	WO 03/049702	06-19-03	Amgem Inc.	

Examiner Signature	/Laura L. Stockton/	Date Considered	12/04/2008
-----------------------	---------------------	--------------------	------------

⁴EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if no longer applicable. ⁵Applicant's unique citation designation number (optional). ⁶See Kinds Code of Patent Document at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.) ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or suggestions you may have as to the amount of time required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Gramercy Technology Park, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LLS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/554,036
		Filing Date	October 20, 2005
		First Named Inventor	Besidski
		Art Unit	Unknown
		Examiner Name	Unknown
Sheet	4	of	4
		Attorney Docket Number	
		101023-1P US	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	A15	FREY, C. et al., "Iminoisoindolinone metal complexes, method for...high-molecular-weight material...containing such a metal complex," & EP, 23889, 19810211, accession 1981:444733 ABSTRACT ONLY		
	A16	MILLER, R. et al., "Schistosoma mansoni: salicylanilides... cercarial penetration of mice," & Experimental Parasitology, 61(3), ppg. 359-68, 1986, accession no. 1986:472101		
	A17	PORTNAYA, B. et al., "Azomethine dyes. IV. Indoaniline...heterocyclic N-substituted 1-hydroxy-2-naphthamides," & Ts. Vses. Nauchn.-Issled. Kinnofotinst. (No. 40) 106-18, 1960 ABSTRACT ONLY		
	A18	SHINKAI, H. et al., "Preparation of amide derivatives as nociception antagonists," & WO, A1, 9948492, 19990930, pp. 113, accession no. 1999:626041		
	A19	SUZUKI, N. et al., "Preparation of imidazole derivatives as gonadotropinreleasing hormone antagonists," & JP, A2, 2000095767, 20000404, pp. 79, accession no. 132:265201		
	A20	CHEMCATS, Accession No. 2001:53212, 24 April 2003, 3-Pyridinecarboxamide,N-(2-methyl-5-benzothiazolyl), CASRN 302953-34-0		
	A21	WILLITZER, H. et al., "Synthesis and antiviral activity of substituted 5-ureido- and 5-thioureidobenzimidazole derivatives," & Pharmazie, 33(1), 30-8, 1978		
	A22	Caterina, M.J., Schumacher, M.A., et. al., Nature 1997 vol. 389, pgs 816 - 824		
	A23	Tominaga, M., Caterina, M.J., et al., Neuron 1998, vol. 21 pgs 531 - 543		
	A24	Walker, et al., J. Pharmacol Exp Ther. 2003 Jan; 304(1):56-62		

Examiner Signature	/Laura L. Stockton/	Date Considered	12/04/2008
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 0.5 hours to complete, including gathering, preparing, and submitting the completed application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LLS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

4

of

2

4

Application Number	10/554,036
Filing Date	October 20, 2005
First Named Inventor	Besidski
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	101023-1P US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A25	Rashid, et al, J Pharmacol Exp Ther. 2003 March;304(3):940-948	
	A26	Hwang and Oh Curr Opin Pharmacol 2002 June; 2(3):235-242	
	A27	Yiangou, et al BJU Int 2001 june; 87(9): 774-779, Szallasi Am J Clin Pathol 2002 118: 110-121	
	A28	STN International, Caplus Acces No. 2004:101143, document no. 140:146168, Moriya, Minoru, et al; "Antagonist of . . . Active Ingredient"; & WO, A1, 2004011440, 20040205, 112	
	A29	STN International File Registry, January 2001 July 30, 2004	
	A30	Mark E. McDonnell, et al.; Bioorganic & Medicinal Chemistry Letters 14 (2004); pages 531-534	

Examiner Signature	/Laura L. Stockton/	Date Considered	12/04/2008
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to cost \$10.00 per application, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LLS/

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.